Register for our free email digests:
Hikma Pharmaceuticals plc
https://www.hikma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hikma Pharmaceuticals plc
Amarin Steps Closer To EU Cardiovascular Risk Market
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
Amarin Builds Sales Infrastructure For EU Vazkepa Launch
With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.
Hikma Opens Discussions To Acquire GSK OTC, Rx Businesses In Egypt, Tunisia
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- EIMC United Pharmaceuticals
- Roxane Laboratories, Inc.
- West-Ward Pharmaceuticals Corp.